drugset / Trial / NCT00923637

Pemetrexed Plus Oxaliplatin as Adjuvant Chemotherapy for Radically Resected Non-Small Cell Lung Cancer

NCT00923637 ↗

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The main purpose of this phase II trial is to evaluate the clinical feasibility-in terms of patients without dose limiting toxicities or premature treatment withdrawal or death-of administering adjuvant chemotherapy of pemetrexed followed by pemetrexed/oxaliplatin immediately post-video-assisted thoracic surgery (VATS) in patients with completely resected Non-Small Cell Lung Cancer (NSCLC).

Timeline

Start
2009-06
Primary completion
2014-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxaliplatin Small molecule 120 mg/m2 Intravenous
Subject Pemetrexed Small molecule 500 mg/m2 Intravenous